| References: |
PTC-209 inhibits both the UTR-mediated reporter expression and endogenous BMI-1 expression in human colorectal HCT116 and human fibrosarcoma HT1080 tumor cells. PTC-209 decreases colorectal tumor cell growth in a BMI-1-dependent way. In addition, PTC-209 impairs colorectal cancer-initiating cells (CICs) through irreversible growth inhibition. PTC-209 (60 mg/kg/day, s.c.) effectively inhibits BMI-1 production in tumor tissue, and halts growth of preestablished tumors in mice bearing primary human colon cancer xenograft, human colon cancer cell lines LIM1215 or HCT116 xenografts. PTC-209 also reduces the frequency of functional colorectal CICs in vivo. For the detailed information of PTC-209, the solubility of PTC-209 in water, the solubility of PTC-209 in DMSO, the solubility of PTC-209 in PBS buffer, the animal experiment (test) of PTC-209, the cell expriment (test) of PTC-209, the in vivo, in vitro and clinical trial test of PTC-209, the EC50, IC50,and Affinity of PTC-209, Please contact DC Chemicals. |
